Payment overview · 2025
General Payments
$655.21
31 reported records · 13 companies
Healthcare provider profile · identity verified
Sandra L. Lee, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · FRESNO, CA · NPI 1376566968
Verified facts
What the public records show
CMS Open Payments records show Sandra L. Lee, PA received $655.21 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $247.89 | 37.8% | 13 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $68.62 | 10.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.37 | 7.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.24 | 6.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.87 | 6.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.58 | 5.4% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $28.23 | 4.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.78 | 3.9% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $24.24 | 3.7% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $22.80 | 3.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.65 | 3.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.24 | 2.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.70 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $655.21 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $135.63 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $76.05 | 4 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $68.62 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.37 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $51.37 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $45.24 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.87 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.87 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.21 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $35.58 | 2 | 2025 |
Source payment records
|
|||||
| OPZELURA Normalized: opzelura |
Drug | Incyte Corporation | $28.23 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.78 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 56 |
| Metformin Hcl | Metformin Hcl | 90 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 61 | 16 |
| Atorvastatin Calcium | Atorvastatin Calcium | 54 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 41 |
| Ezetimibe | Ezetimibe | 45 | 14 |
| Gabapentin | Gabapentin | 42 | 18 |
| Azithromycin | Azithromycin | 38 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 36 |
| Trazodone Hcl | Trazodone Hcl | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Furosemide | Furosemide | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | 12 |
| Losartan Potassium | Losartan Potassium | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Prednisone | Prednisone | 18 | 18 |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 17 | suppressed |
| Repatha Syringe | Evolocumab | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Omeprazole | Omeprazole | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $655.21 · 31 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APTIMA, Auvelity, BREZTRI, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GEMTESA, Kerendia, NURTEC ODT, OPZELURA, PROLIA, QULIPTA, REXULTI, SHINGRIX, THINPREP 2000 PROCESSOR, UBRELVY, Vest Therapy Und, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error